"Vaccines, Attenuated" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity.
| Descriptor ID |
D014613
|
| MeSH Number(s) |
D20.215.894.811
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Vaccines, Attenuated".
Below are MeSH descriptors whose meaning is more specific than "Vaccines, Attenuated".
This graph shows the total number of publications written about "Vaccines, Attenuated" by people in this website by year, and whether "Vaccines, Attenuated" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 5 | 6 |
| 1995 | 1 | 3 | 4 |
| 1996 | 1 | 4 | 5 |
| 1997 | 0 | 3 | 3 |
| 1998 | 1 | 5 | 6 |
| 1999 | 1 | 4 | 5 |
| 2000 | 0 | 6 | 6 |
| 2001 | 1 | 3 | 4 |
| 2002 | 0 | 7 | 7 |
| 2003 | 1 | 5 | 6 |
| 2004 | 0 | 4 | 4 |
| 2005 | 0 | 4 | 4 |
| 2006 | 0 | 4 | 4 |
| 2007 | 3 | 1 | 4 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 4 | 4 |
| 2011 | 0 | 4 | 4 |
| 2012 | 0 | 3 | 3 |
| 2013 | 0 | 4 | 4 |
| 2014 | 2 | 2 | 4 |
| 2015 | 0 | 5 | 5 |
| 2016 | 2 | 7 | 9 |
| 2017 | 0 | 7 | 7 |
| 2018 | 0 | 4 | 4 |
| 2019 | 1 | 5 | 6 |
| 2020 | 1 | 4 | 5 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vaccines, Attenuated" by people in Profiles.
-
Safety and Immunogenicity of Live Viral Vaccines in a Multicenter Cohort of Pediatric Transplant Recipients. JAMA Netw Open. 2023 10 02; 6(10):e2337602.
-
Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/?NS2/?1313/I1314L and RSV/276 in RSV-Seronegative Children. J Infect Dis. 2022 12 13; 226(12):2069-2078.
-
Estimation of the Minimal Rift Valley Fever Virus Protective Neutralizing Antibody Titer in Human Volunteers Immunized with MP-12 Vaccine Based on Protection in a Mouse Model of Disease. Am J Trop Med Hyg. 2022 11 14; 107(5):1091-1098.
-
Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential. PLoS Pathog. 2022 06; 18(6):e1010658.
-
Understanding Variation in Rotavirus Vaccine Effectiveness Estimates in the United States: The Role of Rotavirus Activity and Diagnostic Misclassification. Epidemiology. 2022 09 01; 33(5):660-668.
-
Isolation of a Potently Neutralizing and Protective Human Monoclonal Antibody Targeting Yellow Fever Virus. mBio. 2022 06 28; 13(3):e0051222.
-
Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity Responses. J Infect Dis. 2021 10 28; 224(8):1372-1382.
-
100 years of Mycobacterium bovis bacille Calmette-Gu?rin. Lancet Infect Dis. 2022 01; 22(1):e2-e12.
-
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines. Vaccine. 2020 11 17; 38(49):7708-7715.
-
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 Influenza Season. MMWR Recomm Rep. 2020 08 21; 69(8):1-24.